PAR-25-266-Full-Announcement.html

This is an HTML announcement file for PAR-25-266, a grant opportunity focused on developing novel screening approaches and therapeutic interventions for newborn screenable disorders. The funding opportunity, issued by the Department of Health and Human Services/National Institutes of Health, aims to support research for potentially fatal or disabling conditions identified through newborn screening, as well as "high priority" genetic conditions where screening may be feasible in the near future. "High priority" conditions are defined as those where screening is not currently recommended, but early identification and treatment would significantly benefit infants.

The grant falls under the Child Health and Human Development Extramural Research program (CFDA 93.865) and uses the R21 funding mechanism with an optional clinical trial component. Eligible applicants include a wide range of organizations: tribal governments, public housing authorities, nonprofits, higher education institutions, small businesses, for-profit organizations, state and local governments, and school districts. The focus is on developing both accurate screening tests and demonstrating the benefits of early intervention or treatment, which are crucial criteria for including conditions on newborn screening panels.